They suggested that PRKCZ acts as a potential tumor suppressor in intestinal tumors, prostate cancer, and lung cancer via involvement in metabolism reprogramming [58], suppressing the polarization of macrophages to the M2 phenotype [59], and inhibiting EMT [60]. The gene discussed is PRKCZ; the disease is lung cancer.